Impax Labs Shares Down Sharply After FDA CRL for RYTARY NDA; Canaccord Says Buy the Dip
January 22, 2013 at 11:20 AM EST
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL ), announced early Sunday the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for RYTARY™ (IPX066), an extended-release capsule formulation of carbidopa-levodopa, a potential treatment for the symptomatic treatment of Parkinson's disease currently under review